References
- Levine DP. Vancomycin: a history. Clin. Infect. Dis. 42(Suppl. 1), S5–S12 (2006).
- Powers JH. Increasing the efficiency of clinical trials of antimicrobials: the scientific basis of substantial evidence of effectiveness of drugs. Clin. Infect. Dis. 45(Suppl. 2), S153–S162 (2007).
- Lumpkin MM, Burlington DB, Peck CC, Kessler D. Preface: FDA guidelines for the clinical evaluation of anti-infective drug. Clin. Infect. Dis. 15, S3 (1992).
- Beam TR Jr, Gilbert DN, Kunin CM. General guidelines for the clinical evaluation of anti-infective drug products. Clin. Infect. Dis. 15(Suppl. 1) S1–S346 (1992).
- Blum MD, Graham DJ, McCloskey CA. Temafloxacin syndrome: review of 95 cases. Clin. Infect. Dis. 18(6), 946–950 (1994).
- Ross DB. The FDA and the case of Ketek. N. Engl. J. Med. 356(16), 1601–1604 (2007).
- Echols RM. Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world. Ann. NY Acad. Sci. 1241, 153–161 (2011).
- No authors listed. Leading edge: shifting goalposts in antibiotic approval. Lancet Infect. Dis. 6, 751 (2006).
- Temple RJ. Preamble to accelerated approval amendment. Federal Register 57 13234–13242 (1992).
- Temple RJ. A regulatory authority’s opinion about surrogate end points. In: Clinical Measurement in Drug Evaluation. Nimmo WS, Tucker GT (Eds). John Wiley & Sons Ltd, NY, USA, 4 (1995).
- Biomarkers Definitions Working Group. Biomarkers and surrogate end points: preferred definitions and conceptual framework. Clin. Pharmacol. Therapeut. 69(3), 89–95 (2001).
- US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Guidance for Industry. Complicated Urinary Tract Infections: Developing Drugs for Treatment. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (2012).
- Morrison T. Trius back on track with SPA for pivotal trial of antibiotic torezolid. BioWorld Today 17 June (2010).
- Toerner JG, Burke L, Komo S, Papadopoulos E. A collaborative model for end point development for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. Clin. Infect. Dis. 55, 1–2 (2012).
- Talbot G, Powers JH, Fleming TR et al. Progress on developing end points for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin. Infect. Dis. 55, 1–8 (2012).
- Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48(1), 1–12 (2009).
- Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG; Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42(5), 657–668 (2006).
- Infectious Disease Society of America. Combating antimicrobial resistance: policy recommendations to save lives. Clin. Infect. Dis. 52(S5), S397–S428 (2011).
- The Innovative Medicines Initiative (IMI) has launched a euro 223 million (US$280 million) New Drugs 4 Bad Bugs (ND4BB) programme to spur the development of antibiotics. Nat. Rev. Drug Discov. 11, 507 (2012).
Websites
- Wikipedia. The Long and Winding Road. http://en.wikipedia.org/wiki/The_Long_and_Winding_Road
- FDA. FDA fundamentals. www.fda.gov/AboutFDA/Transparency/Basics/ucm192695.htm
- FDA. FDA history – part I. The 1906 Food and Drugs Act and its enforcement. www.fda.gov/AboutFDA/WhatWeDo/History/Origin/ucm054819.htm
- FDA. Public symposium commemorating 100 years of biologics regulation. www.fda.gov/downloads/AboutFDA/WhatWeDo/History/ProductRegulation/100YearsofBiologicsRegulation/UCM070369.pdf
- FDA. FDA history – part II. The 1938 Food, Drug, and Cosmetic Act. www.fda.gov/AboutFDA/WhatWeDo/History/Origin/ucm054826.htm
- FDA. FDA and clinical drug trials: a short history. www.fda.gov/AboutFDA/WhatWeDo/History/Overviews/ucm304485.htm
- FDA. Guidance for Industry. Animal models – essential elements to address efficacy under the animal rule. US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research (January 2009). www.fda.gov/downloads/Drugs/guidanceComplianceRegulatoryInformation/Guidances/UCM078923.pdf
- Infectious Diseases Society of America. Bad bugs, no drugs. www.idsociety.org/uploadedFiles/IDSA/Policy_and_Advocacy/Current_Topics_and_Issues/Antimicrobial_Resistance/10x20/Images/Bad%20Bugs%20no%20Drugs.pdf#search=%22bad bugs no drugs%22
- Trovafloxacin and alatrofloxacin NDA review and product label. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist
- FDA. PDUFA legislation and background. www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm144411.htm
- Federal Register. Volume 72, number 114 (Thursday June 14 2007), Notices. Otsuka Pharmaceutical Co., Ltd. Withdrawal of approval of a new drug application. www.fda.gov/OHRMS/DOCKETS/98fr/E7-11496.pdf
- FDA. Drug approval package. Trovan tablets and Trovan i.v. (trovafloxacin mesylate and alatrofloxacin mesylate). www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.cfm
- FDA. FDA 9 June 1999 Trovan (trovafloxacin)/alatrofloxacin mesylate) interim recommendations. www.fda.gov/ForConsumers/ConsumerUpdates/ucm053103.htm
- USA Today. Rubin R. How did Vioxx debacle happen? (10/12/2004). www.usatoday.com/news/health/2004-10-12-vioxx-cover_x.htm
- Kweder SL. Drug regulation in controversy: Vioxx (10 November 2004). www.fda.gov/downloads/Drugs/DrugSafety/…/ucm106877.ppt
- United States Senate. Opening statement of US Senator Chuck Grassley of Iowa. Chairman, Senate Committee on Finance Hearing – FDA Merck and Vioxx: putting patient safety first? Thursday 18 November 2004. www.finance.senate.gov/imo/media/doc/111804cg.pdf
- New York Times (8 June 2006). Harris G. Halt is urged for trials of antibiotic in children. www.nytimes.com/2006/06/08/science/08drug.html
- The New York Times (19 July 2006). Harris G. Approval of antibiotic worried safety officials. www.nytimes.com/2006/07/19/health/19fda.html?scp=7&sq=US+Senator+Says+FDA+Not+Cooperating+on+Antibiotic+june+12%2C+2006&st=nyt
- FDA Center for Drug Evaluation and Research. Guidance, compliance and regulatory information. Clinical/antimicrobial guidances. www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064980.htm
- FDA. Anti-Infective Drugs Advisory Committee Meeting (18 November 2008). Approach to determining non-inferiority margin in cSSSI. www.fda.gov/ohrms/dockets/ac/08/slides/2008-4394s1-01-FDA.pdf
- Anti-Infective Drugs Advisory Committee. Briefing Document. End points and clinical trial issues in community-acquired bacterial pneumonuia. 2011 Foundation for The National Institutes of Health (FNIH) Biomarkers Consortium Team. Recommendations to the FDA for interim end points for clinical trials in community acquired pneumonia. FNIH Biomarkers Consortium Project Team CABP Docket ID: FDA-2009-D-0136. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm275823.pdf
- FDA medical review, NDA-022106 (doripenem), part 1, 2007, appendix 1, 18–27. Justification of non-inferiority margin for complicated intra-abdominal infections. www.fda.gov/downloads/Drugs/DrugSafety/…/ucm106877.ppt
- FDA. Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims. US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health (December 2009). www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf
- The National Academies Press. Evaluation of biomarkers and surrogate end points in chronic disease (page 6). www.nap.edu/openbook.php?record_id=13038&page=6
- FDA. Guidance for Industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research. August 2010 Revision 127. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071185.pdf
- FDA. Guidance for Industry. Community-acquired bacterial pneumonia: developing drugs for treatment. US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research. March 2009 Revision 1. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM123686.pdf
- FDA. Guidance for Industry. Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia: developing drugs for treatment. US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research. November 2010. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM234907.pdf
- FDA. Issues in the design of clinical trials for antibacterial drugs for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). A workshop co-sponsored by the FDA, the Infectious Diseases Society of America, the American Thoracic Society, the Society of Critical Care Medicine and the American College of Chest Physicians. 31 March and 1 April 2009. www.fda.gov/downloads/Drugs/NewsEvents/UCM169929.pdf
- FDA. Anti-Infective Drugs Advisory Committee. End points and clinical trial issues in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. 4 November 2011. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM275820.pdf
- FDA. Regulatory information. Guidances search. www.fda.gov/RegulatoryInformation/Guidances/default.htm
- Paratek wins agreement with FDA on special protocol assessment (SPA) for Phase 3 study in community-acquired bacterial pneumonia (CABP). Paratek Pharmaceuticals (28 March 2012). www.paratekpharm.com/press/032812_SPA_ECCMID_release.pdf
- Young, D. ALS pursues first-of-its-kind antibiotic superiority trial. 2010 BioWorld Today 21. www.bioworld.com/bioworld_search/als%2Bpursues
- FDA. Drug development tools (DDT) qualification programs. www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/default.htm
- Daily Drug Bulletin (26 April 2012). Throckmorton D. FDA guidance on antibiotics, abuse-deterrent formulations forthcoming, CDER official says. http://fdanews.com/newsletter/article?issueId=15722&articleId=145899
- Food and Drug Administration Safety and Innovation Act (S.3187, section 806).Guidance on pathogen-focused anti-bacterial drug development. www.gpo.gov/fdsys/pkg/BILLS-112s3187enr/pdf/BILLS-112s3187enr.pdf
- EMA (21 June 2012). Addendum to the note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/EWP/558/95 REV 2) to address indication-specific clinical data. www.ema.europa.eu/ema/doc_index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500129443&murl=menus/document_library/document_library.jsp&mid=0b01ac058009a3dc
- FDA. Janssen WF. The story of the laws behind the labels, part I: the 1906 Food and Drugs Act (from FDA Consumer, June 1981). www.fda.gov/AboutFDA/WhatWeDo/History/Overviews/ucm056044.htm